Veterinary ophthalmologists bridge the gap between clinical surgery and comparative research, ensuring regulatory compliance ...
Fannin Partners Awarded $300K Phase I SBIR Grant from the National Eye Institute to Advance First-in-Class Non-VEGF-Targeted Therapeutics for Wet AMD ...
Glaucoma is a blinding disease caused by damage to the optic nerve, leading to permanent vision loss. The main risk factor is ...
Multiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 ...
Chris R. Alabiad, MD: There wasn’t one single national rule change in 2025 that transformed residency training overnight.
The FDA approved a refillable ranibizumab implant for DME, offering a less frequent treatment alternative to monthly injections. A case series suggested a potential link between semaglutide and ...
The most-read ophthalmology biosimilar stories of 2025 included FDA approvals and real-world data. The continued expansion of the biosimilar market into ophthalmology is helping to redefine treatment ...
As the 2025 calendar year rounds out, CNBC has ranked the top-25 college athletic programs by valuation. Texas has skyrocketed to the No. 1 spot, worth $1.48 billion. This number is 16% more than it ...
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Eduardo C. Alfonso, MD, and Steven H. Collis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback